ADAR1 Capital Management, LLC, 10% Owner at TENAX THERAPEUTICS, INC. (TENX), bought 1,025,867 shares at $1.78 ($1.8M) on 2026-08-20, disclosed to the SEC on 2026-08-24.
ADAR1 Capital Management, LLC executed the largest-ever insider purchase in TENX history, buying 202,124 shares at $1.78 on August 20, 2026, signaling confidence in the stock's post-crash valuation. This move comes just days after the company announced a revised registrational strategy for its levosimendan drug following a Phase III trial failure.
The stock has crashed 87.93% over the last 30 days and is currently trading at $1.75, sitting just 32.58% above its 52-week low of $1.32.
1) FDA submission of subgroup data from the failed Phase III trial on or around August 11, 2026; 2) Upcoming earnings report on {date} (needs manual review); 3) Analysts currently project a 121.36% upside to the current price target.
The stock faces significant risk due to the failure of the Phase III LEVEL trial, which missed its primary endpoint and caused the stock to plummet nearly 90% in a single day.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.78 | 202,124 | $360K | 19.8% |
| 2 | $1.77 | 716,369 | $1.3M | 69.8% |
| 3 | $1.75 | 107,374 | $188K | 10.4% |
| Total | $1.77 avg | 1,025,867 | $1.8M | 100% |
| Filing → |
| INM | BUY | 2026-10-05 | $57K | — | Filing → |
| INM | BUY | 2026-09-16 | $118K | — | Filing → |
| TENX | BUY | 2026-09-08 | $1.6M | — | Filing → |